ReviewNature reviews. Clinical oncology2019
Vessel co-option in cancer.
Review in Nature reviews. Clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 261 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
261 citing papers in PubMed, 2 syntheses or guidelines pooled it, 436 citations in OpenAlex.
- Non-oncologic to oncologic drug: A systematic review of drug repurposing in cancer.Cancer chemotherapy and pharmacology · 2025Pooled it
- Transcatheter Arterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy Versus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024Pooled it
- DCE-MRI kinetic heterogeneity facilitates the discrimination of benignity and malignancy of breast in combination with the DWI and morphological features.European journal of radiology open · 2026Article
- Linking preclinical models with functional imaging and artificial intelligence to decode tumor angiogenesis.Pharmacological reports : PR · 2026Review
- Mycn regulates vascular development through PI3K signaling pathway in zebrafish.Developmental dynamics : an official publication of the American Association of Anatomists · 2026Article
- The emerging roles of cerebral pericytes in brain metastasis.Neuro-oncology · 2026Review
- Article
- Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response.Nature reviews. Cancer · 2026Review
- The Invasive Margin of Glioblastoma as a Molecular Ecosystem: Spatial Heterogeneity, Tumor-Host Interactions, and Therapeutic Opportunities.International journal of molecular sciences · 2026Review
- Integrin inhibition differentially remodels vascular networks in lung metastases driven by vessel co-option or angiogenesis.Angiogenesis · 2026Article
- Review
- PRMT6 acts as a pro-angiogenic factor in colorectal cancer.Cell death discovery · 2026Article
- The lethal symbiont: exploring the pathophysiology of cancer.Physiological reviews · 2026Review
- Endoglin (CD105) overexpression is associated with an immunosuppressive tumor microenvironment in murine lung cancer models and human lung adenocarcinoma.Scientific reports · 2026Article
- The vascular niche: an orchestrator of the spatiotemporal dynamics of distant metastasis.Acta pharmacologica Sinica · 2026Review
- Identification of a migracytosis and angiogenesis-associated lncRNAs signature in immunotherapy in breast cancer.Journal of applied genetics · 2026Article
- LRP-1/CD44-targeted regorafenib nano-delivery system leveraging anti-angiogenesis and synergistic cytotoxicity against peritoneal metastasis of colorectal cancer.Bioactive materials · 2026Article
- [Molecular mechanisms and clinical applications of anti-angiogenic therapy in precision treatment of breast cancer].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Review
- Review
- Optical coherence tomography angiography in evaluating the response of ocular surface squamous neoplasia to topical immunotherapy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
201 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
All solid tumours require a vascular supply in order to progress. Although the ability to induce angiogenesis (new blood vessel growth) has long been regarded as essential to this purpose, thus far, anti-angiogenic therapies have shown only modest efficacy in patients. Importantly, overshadowed by the literature on tumour angiogenesis is a long-standing, but continually emerging, body of research indicating that tumours can grow instead by hijacking pre-existing blood vessels of the surrounding nonmalignant tissue. This process, termed vessel co-option, is a frequently overlooked mechanism of tumour vascularization that can influence disease progression, metastasis and response to treatment. In this Review, we describe the evidence that tumours located at numerous anatomical sites can exploit vessel co-option. We also discuss the proposed molecular mechanisms involved and the multifaceted implications of vessel co-option for patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.